Acceleron Pharma Inc (XLRN):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(SWOT20MY1319)
◆英語タイトル:Acceleron Pharma Inc (XLRN) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1319
◆発行会社(リサーチ会社):GlobalData
◆発行日:2020年4月
◆ページ数:48
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Acceleron Pharma Inc (XLRN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acceleron Pharma Inc (Acceleron) is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutics to treat serious and rare diseases. Reblozyl is the company’s only commercial product used for the treatment of anemia with beta-thalassemia patients who require regular red blood cell (RBC) transfusion. The company’s lead therapeutic candidate, luspatercept-aamt is in Phase III study for the treatment of anemia and associated complications in myelodysplastic syndromes, beta-thalassemia and myelofibrosis. Its other pipeline products are being developed for the treatment of, neuromuscular , pulmonary and associated diseases. The company partners with various biopharmaceutical companies and research institutes to advance the development of its lead products. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.

Acceleron Pharma Inc Key Recent Developments

Mar 09,2020: Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
Feb 27,2020: Acceleron reports fourth quarter and full year 2019 operating and financial results
Jan 23,2020: Acceleron announces change to executive management team
Dec 31,2019: Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Acceleron Pharma Inc – Key Facts
Acceleron Pharma Inc – Key Employees
Acceleron Pharma Inc – Key Employee Biographies
Acceleron Pharma Inc – Major Products and Services
Acceleron Pharma Inc – History
Acceleron Pharma Inc – Company Statement
Acceleron Pharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Acceleron Pharma Inc – Business Description
Acceleron Pharma Inc – Corporate Strategy
Acceleron Pharma Inc – SWOT Analysis
SWOT Analysis – Overview
Acceleron Pharma Inc – Strengths
Acceleron Pharma Inc – Weaknesses
Acceleron Pharma Inc – Opportunities
Acceleron Pharma Inc – Threats
Acceleron Pharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Acceleron Pharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 23, 2020: Acceleron announces change to executive management team
Dec 31, 2019: Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
Dec 30, 2019: Acceleron and Fulcrum Therapeutics announce pulmonary research and discovery collaboration agreement
Dec 09, 2019: Acceleron appoints Jay T. Backstrom, M.D., M.P.H., to newly created role as head of research and development
Dec 06, 2019: Acceleron appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors
Dec 04, 2019: Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings
Nov 06, 2019: Acceleron reports third quarter 2019 operating and financial results
Aug 05, 2019: Acceleron reports second quarter 2019 operating and financial results
Jun 10, 2019: Acceleron announces retirement of Director and Co-Founder Tom Maniatis
May 09, 2019: Acceleron reports first quarter 2019 operating and financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Acceleron Pharma Inc, Key Facts
Acceleron Pharma Inc, Key Employees
Acceleron Pharma Inc, Key Employee Biographies
Acceleron Pharma Inc, Major Products and Services
Acceleron Pharma Inc, History
Acceleron Pharma Inc, Subsidiaries
Acceleron Pharma Inc, Key Competitors
Acceleron Pharma Inc, Ratios based on current share price
Acceleron Pharma Inc, Annual Ratios
Acceleron Pharma Inc, Annual Ratios (Cont...1)
Acceleron Pharma Inc, Interim Ratios
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Acceleron Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Acceleron Pharma Inc, Performance Chart (2015 - 2019)
Acceleron Pharma Inc, Ratio Charts
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Acceleron Pharma Inc (XLRN):企業の財務・戦略的SWOT分析(Acceleron Pharma Inc (XLRN) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆